Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.88 HKD | -0.22% | -1.33% | +26.68% |
Jun. 06 | Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic | RE |
Jun. 06 | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company shows low valuation levels, with an enterprise value at 0.6 times its sales.
- The company appears to be poorly valued given its net asset value.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.68% | 2.07B | - | ||
+45.82% | 765B | C+ | ||
+40.95% | 632B | B | ||
-6.16% | 354B | C+ | ||
+19.86% | 331B | B- | ||
+9.32% | 299B | C+ | ||
+18.45% | 248B | B+ | ||
+11.88% | 216B | B- | ||
-0.78% | 219B | A+ | ||
+5.90% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 3933 Stock
- Ratings The United Laboratories International Holdings Limited